4.1.4.2.1.4. summary evidence recommendations anticholinergic drugs. summary evidenceleanticholinergic drugs effective improving oab symptoms, decreasing uui episodes, decreasing daily urgency frequency episodes increasing mean voided volumes, compared placebo.1aanticholinergic drugs caused higher adverse events placebo including dry mouth, cognitive impairment, constipation.1aonce daily (er) formulations associated lower rates adverse events compared ir preparations.1btransdermal oxybutynin associated lower rates dry mouth oral anticholinergic drugs higher rate withdrawal due skin reactions.1bhigher doses anticholinergic drugs effective improve oab symptoms exhibit higher risk adverse effects.1ano anticholinergic drug clearly superior another cure improvement oab/uui.1athe combination antimuscarinics plus another treatment modality effective antimuscarinics alone improving oab.1aadherence anticholinergic treatment low decreases time lack efficacy, adverse events and/or cost.2amost patients stop anticholinergic agents within first three months.2a recommendationsstrength ratingoffer anticholinergic drugs woman overactive bladder (oab) fail conservative treatment.strongconsider extended-release formulations anticholinergic drugs whenever possible.strongif anticholinergic treatment proves ineffective, consider dose escalation, offering alternative anticholinergic formulation, use mirabegron (alone combination anticholinergic).strongencourage early review (of efficacy adverse effects) patients anticholinergic medication oab.strong